Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death.

Hodge DL, Subleski JJ, Reynolds DA, Buschman MD, Schill WB, Burkett MW, Malyguine AM, Young HA.

J Interferon Cytokine Res. 2006 Oct;26(10):706-18.

PMID:
17032165
3.

Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death.

Chandrasekar B, Vemula K, Surabhi RM, Li-Weber M, Owen-Schaub LB, Jensen LE, Mummidi S.

J Biol Chem. 2004 May 7;279(19):20221-33. Epub 2004 Feb 11.

4.

A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases.

Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami A, Migita K, Kawabe Y, Tsujihata M, Anderson P, Eguchi K.

Arthritis Rheum. 2001 Apr;44(4):884-92.

6.

IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma.

Walker W, Aste-Amezaga M, Kastelein RA, Trinchieri G, Hunter CA.

J Immunol. 1999 May 15;162(10):5894-901.

7.

Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice.

Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA, Siekierka JJ, Peterson PA, Fung-Leung WP.

J Exp Med. 1999 Apr 5;189(7):1129-38.

9.

Differential regulation of human NK cell-associated gene expression following activation by IL-2, IFN-alpha and PMA/ionomycin.

Mori S, Jewett A, Cavalcanti M, Murakami-Mori K, Nakamura S, Bonavida B.

Int J Oncol. 1998 May;12(5):1165-70.

PMID:
9538144
11.

Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA.

J Immunol. 1999 Apr 15;162(8):4511-20.

12.
13.

Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.

Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B.

J Exp Med. 1998 Dec 21;188(12):2375-80.

15.

A potential role for interleukin-15 in the regulation of human natural killer cell survival.

Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA.

J Clin Invest. 1997 Mar 1;99(5):937-43.

16.

Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease.

Liu Z, Yang L, Cui Y, Wang X, Guo C, Huang Z, Kan Q, Liu Z, Liu Y.

Inflamm Bowel Dis. 2009 Aug;15(8):1133-44. doi: 10.1002/ibd.20923.

PMID:
19322899
17.

The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.

Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, Fadeel B, Zheng C.

Mol Immunol. 2010 Aug;47(14):2388-96. doi: 10.1016/j.molimm.2010.05.003. Epub 2010 Jun 9.

PMID:
20542572
18.

IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12.

Matikainen S, Paananen A, Miettinen M, Kurimoto M, Timonen T, Julkunen I, Sareneva T.

Eur J Immunol. 2001 Jul;31(7):2236-45.

PMID:
11449378
19.

Characteristics of the killing mechanism of human natural killer cells against hepatocellular carcinoma cell lines HepG2 and Hep3B.

Kim HR, Park HJ, Park JH, Kim SJ, Kim K, Kim J.

Cancer Immunol Immunother. 2004 May;53(5):461-70. Epub 2003 Nov 28.

PMID:
14648068
20.

Supplemental Content

Support Center